Sutent Given U.S. Approval
The United States Food and Drug Administration (FDA) announced Jan. 26 that it has approved Sutent (sunitinib) for patients with gastrointestinal stromal tumors (GIST) and advanced kidney cancer. It was the first time the agency has approved a new oncology product for two cancers simultaneously.